Remarkable Intracranial Response to Sotorasib in a Patient With KRAS(G12C)-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report

Sotorasib is a KRAS(G12C) inhibitor that recently received approval for use in locally advanced or metastatic KRAS(G12C)-mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Justin, Marks, Jennifer A., Alzeer, Ali H., Sloan, Emily A., Varghese, Reshma, Paudel, Nitika, Reuss, Joshua E., Bergquist, Peter J., Liu, Stephen V., Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719091/
https://www.ncbi.nlm.nih.gov/pubmed/36471683
http://dx.doi.org/10.1016/j.jtocrr.2022.100428
Descripción
Sumario:Sotorasib is a KRAS(G12C) inhibitor that recently received approval for use in locally advanced or metastatic KRAS(G12C)-mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports describing efficacy of sotorasib on untreated brain metastases. We present a case of a patient with active untreated brain metastases with resulting disorientation and weakness who has radiographic response and complete resolution of neurologic symptoms with sotorasib. Our case illustrates the intracranial activity of sotorasib, but additional studies are needed to characterize the intracranial response rate and duration of response in these patients.

Ejemplares similares